D-1052-2019 Class II Ongoing

Recalled by Rising Pharmaceuticals, Inc. — Saddle Brook, NJ

FDA drug recall D-1052-2019 was initiated by Rising Pharmaceuticals, Inc. on Mar 7, 2019 and is designated Class II. Reason for recall: CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products The recall status is ongoing. Affected quantity: 30,530 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2019
Initiation Date
Mar 7, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
30,530 bottles

Product description

Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ, Manufactured by: Aurolife Pharma LLC, Dayton, NJ ---- NDC 52343-122-30

Reason for recall

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Distribution pattern

Product was distributed to 6 major distributors who may have further distributed the product throughout the United States.

Code information

470170038A, exp. date 10/31/2019 470180010A, exp. date 02/29/2019 470180012A, exp. date 03/31/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1052-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1052-2019. Report a data issue: hello@regdatalab.com.